Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarperprumig in ANCA-Associated Vasculitis (I TRANSCEND)
NCT07160608Phase 2Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of tarperprumig in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Alexion Pharmaceuticals. Started Nov 2025; status: active, not recruiting.
02
Drugs
tarperprumig
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07160608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160608.